Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors

Fig. 6

Exacerbated ERphagy induced by the combination of NU7441 and CV-B5/F degraded STING activated by nuclear cGAS recruited by DSBs. a NCI-H460 was treated with 1 μM NU7441, 0.01 MOI CV-B5/F, or a combination for 24 h. Immunoblots of anti-viral proteins including IRF9 and p-STAT1 were detected. b NCI-H460 cells were treated with 1 μM NU7441, 0.01 MOI CV-B5/F, or a combination for 24 h. FAM134B (a marker of ERphagy) and STING were determined by western blot. c NCI-H460 cells knocked down with shRNA for RIG-I were treated with 1 μM NU7441, 0.01 MOI CV-B5/F, or a combination for 24 h. RIG-I, FAM134B and STING were determined by western blot. Gray values of NC, shRNA-1 and shRNA-2 were compared separately. d NCI-H460 cells overexpressing RIG-I were treated with 1 μM NU7441, 0.01 MOI CV-B5/F, or a combination for 24 h. RIG-I, FAM134B and STING were determined by western blot. Gray values of NC, OE-1 and OE-2 were compared separately. e, f NCI-H460 cells were treated with 1 μM NU7441 or 1 μM KU60019, 0.01 MOI CV-B5/F, or a combination for 24 h. Immunofluorescence of cGAS of nuclear was analyzed by confocal microscopy. Mean gray value of cGAS in nuclear and cytoplasma was separately analyzed by Image J software (n = 20)

Back to article page